Ultimately, 706 participants met the eligibility criteria and were randomly assigned to one of several treatment arms: once-weekly subcutaneous injections of Cagrilintide at doses of 0.3, 0.6, 1.2, 2.4, or 4.5 mg, once-daily liraglutide 3.0 mg, or a volume-matched placebo
Many popular peptides are currently only available on the black and grey market
If you're unable to inject, standalone oral BPC-157 formulations may be an alternative for gut-specific benefits
Always verify vial vacuum and seal integrity before laboratory use
GCL is composed of a catalytic (GCLC, Mr ~73 kDa) and a modifier (GCLM, Mr ~31 kDa) subunit [32] (summarized in Fig